SYRE · Spyre Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $60.41M | - | $45.25M | $40.15M | $41.62M | - | $44.74M | $32.64M | $34.93M | - |
| SG&A | $15.23M | - | $11.64M | $11.79M | $11.94M | - | $10.65M | $11.51M | $12.85M | - |
| Total Operating Expenses | $45.64M | - | $56.89M | $41.94M | $53.57M | - | $55.39M | $44.15M | $47.77M | - |
| D&A | - | - | - | - | - | - | - | - | $0 | - |
| Operating Income | ($45.64M) | - | ($56.89M) | ($41.94M) | ($53.57M) | - | ($55.39M) | ($44.15M) | ($47.77M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | ($15.0K) | - | $18.0K | $0 | $32.0K | - |
| Net Income | ($69.00M) | - | ($11.18M) | ($36.72M) | ($44.77M) | - | ($69.03M) | ($38.84M) | ($43.86M) | - |
| EPS - Basic | - | - | - | - | - | - | ($1.36) | ($0.86) | ($1.20) | - |
| EPS - Diluted | ($0.74) | - | - | - | - | - | ($1.36) | ($0.86) | ($1.20) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $97.19M | $85.72M | $64.90M | $81.66M | $48.49M | $89.42M | $71.58M | $45.14M | $227.55M | $188.89M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | $5.17M | $3.23M | $3.11M | $896.0K |
| Current Assets | $763.95M | $777.78M | $504.60M | $538.83M | $569.77M | $608.47M | $421.08M | $435.74M | $487.27M | $341.53M |
| Total Assets | $763.95M | $777.78M | $504.60M | $538.83M | $569.78M | $608.48M | $421.09M | $436.07M | $487.60M | $341.86M |
| Current Liabilities | $85.16M | $58.69M | $46.27M | $83.06M | $70.68M | $54.06M | $57.54M | $22.12M | $42.82M | $31.98M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $93.14M | $62.55M | $49.50M | $83.06M | $87.17M | $90.68M | $93.70M | $61.68M | $81.93M | $73.29M |
| Stockholders' Equity | $670.81M | $715.24M | $455.10M | $455.77M | $482.61M | $517.80M | $327.39M | $374.38M | $152.27M | $184.02M |
| Retained Earnings | ($1.20B) | ($1.13B) | ($1.07B) | ($1.05B) | ($1.02B) | ($972.43M) | ($916.14M) | ($847.11M) | ($808.27M) | ($764.41M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($57.37M) | - | - | - | ($40.99M) | - | - | - | ($28.54M) | - |
| Investing Cash Flow | $56.58M | - | - | - | ($61.0K) | - | - | - | ($104.96M) | - |
| Financing Cash Flow | $12.26M | - | - | - | $125.0K | - | - | - | $172.16M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.0% | - | -2.2% | -6.8% | -7.9% | - | -16.4% | -8.9% | -9.0% | - |
| Return on equity | -10.3% | - | -2.5% | -8.1% | -9.3% | - | -21.1% | -10.4% | -28.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 8.97 | 13.25 | 10.90 | 6.49 | 8.06 | 11.26 | 7.32 | 19.70 | 11.38 | 10.68 |
| Quick ratio | 8.97 | 13.25 | 10.90 | 6.49 | 8.06 | 11.26 | 7.32 | 19.70 | 11.38 | 10.68 |
| Cash ratio | 1.14 | 1.46 | 1.40 | 0.98 | 0.69 | 1.65 | 1.24 | 2.04 | 5.31 | 5.91 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.14 | 1.09 | 1.11 | 1.18 | 1.18 | 1.18 | 1.29 | 1.16 | 3.20 | 1.86 |
| Liabilities / Assets | 0.12 | 0.08 | 0.10 | 0.15 | 0.15 | 0.15 | 0.22 | 0.14 | 0.17 | 0.21 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | 4.6x | 2.8x | 9.1x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | -100.0% | -100.0% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 14.8% | - | -2.7% | 5.0% | -12.1% | - | -202.1% | 72.3% | -154.0% | - |
| Net income growth (YoY) | -54.1% | - | 83.8% | 5.5% | -2.1% | - | -72.1% | 82.1% | -138.1% | - |
| EPS growth (YoY) | - | - | - | - | - | - | 85.4% | 62.1% | -224.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 39.0% | 38.1% | 39.0% | 21.7% | 216.9% | 181.4% | - | - | 352.5% | 265.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$886.0K totalDevelopment Fee And Royalty$886.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Spyre Therapeutics against the 5 most active filers in the same SIC group.